.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,669,234

« Back to Dashboard

Details for Patent: 8,669,234

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (San Mateo, CA), Kato; Darryl (San Francisco, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Mitchell; Michael L. (Castro Valley, CA), Parrish; Jay P. (El Dorado Hills, CA), Taylor; James (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster, CA)
Filing Date:Jun 07, 2012
Application Number:13/491,446
Claims:1. A compound of Formula I: ##STR01313## wherein each R.sup.1 is independently: ##STR01314## wherein R.sup.2 is: ##STR01315## wherein T.sup.1 is ##STR01316## or absent; wherein T.sup.2 ##STR01317## wherein L.sup.1 is a thienothiophene ring; wherein L.sup.2 is ##STR01318## or, ##STR01319## or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, further comprising a therapeutic agent selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

4. The pharmaceutical composition according to claim 3, further comprising a nucleoside analogue.

5. The pharmaceutical composition according to claim 4, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

6. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 1.

7. A compound selected from the group consisting of: ##STR01320## ##STR01321## or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 7 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, further comprising a therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

10. The pharmaceutical composition of claim 9, further comprising a nucleoside analogue.

11. The pharmaceutical composition of claim 10, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

12. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc